Zealand Pharma A/S (OTCMKTS:ZLDPF) Downgraded to “Hold” Rating by Berenberg Bank

Zealand Pharma A/S (OTCMKTS:ZLDPF) was downgraded by equities researchers at Berenberg Bank from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other brokerages also recently weighed in on ZLDPF. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Three investment analysts have rated the stock with a Strong Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, Zealand Pharma A/S currently has an average rating of “Moderate Buy”.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF stock opened at $45.01 on Wednesday. The firm has a 50-day moving average price of $47.90 and a 200 day moving average price of $57.22. Zealand Pharma A/S has a twelve month low of $35.93 and a twelve month high of $83.12. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of 3.34 and a beta of 0.86. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. The firm had revenue of $5.33 million during the quarter, compared to the consensus estimate of $2.81 million. Research analysts forecast that Zealand Pharma A/S will post 2.37 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.